Match!
Fernando Flexa Ribeiro Filho
Federal University of São Paulo
12Publications
8H-index
355Citations
Publications 12
Newest
#1Bianca de Almeida Pititto (UNIFESP: Federal University of São Paulo)
#2Fernando Flexa Ribeiro Filho (UNIFESP: Federal University of São Paulo)H-Index: 8
Last.Sandra Roberta Gouvea Ferreira (UNIFESP: Federal University of São Paulo)H-Index: 30
view all 6 authors...
Materials and methods A sample of 998 individuals from the ELSA-Brazil (35-54 yrs.) without cardiovascular disease or diabetes was stratified according to E-selectin tertiles. Traditional risk factors, inflammatory markers and categories of coronary artery calcium (CAC) score were evaluated across the tertiles by ANOVA or chi-squared test. In linear regression models, associations of E-selectin levels with insulin resistance index, adjusted for age, sex and adiposity were tested.
Source
#1Sonia Maria Togeiro (UNIFESP: Federal University of São Paulo)H-Index: 16
#2Glaucia Carneiro (UNIFESP: Federal University of São Paulo)H-Index: 11
Last.Sergio Tufik (UNIFESP: Federal University of São Paulo)H-Index: 67
view all 8 authors...
Objective: Epidemiologic studies that control for potential confounders are needed to assess the independent associations of obstructive sleep apnea (OSA) with metabolic abnormalities. The aim of our study was to evaluate the associations of OSA with metabolic abnormalities among the adult population of Sao Paulo, Brazil. Design and Methods: Questionnaires were applied face-to-face, full night polysomnography (PSG) was performed, and blood samples were collected in a population-based survey in S...
52 CitationsSource
#1Maria Teresa Zanella (UNIFESP: Federal University of São Paulo)H-Index: 19
#2Fernando Flexa Ribeiro Filho (UNIFESP: Federal University of São Paulo)H-Index: 8
Central obesity have an important impact on the development of risk factors for coronary heart disease, including dislipidemia, glucose intolerance, insulin resistance and hypertension. These factors contribute to building cardiovascular (CV) disease as a major cause of death. The approach to obesity therapy should be designed to reduce CV risk and mortality. Diet and lifestyle changes remain the cornerstones of therapy for obesity, but the resultant weight loss is often small and long-term succ...
17 CitationsSource
#1Glaucia Carneiro (UNIFESP: Federal University of São Paulo)H-Index: 11
#2Fernando Flexa Ribeiro Filho (UNIFESP: Federal University of São Paulo)H-Index: 8
Last.Maria Teresa Zanella (UNIFESP: Federal University of São Paulo)H-Index: 19
view all 5 authors...
Previous studies have shown Obstructive Sleep Apnea (OSA) as a risk factor for development of cardiovascular and cerebrovascular disease. However, controversies remain as to whether these changes are consequences of the associated obesity or OSA itself results in endocrine and metabolic changes, including impairment of insulin sensitivity, growth hormone, secretion inflammatory cytokines alterations, activation of peripheral sympathetic activity, and hipothalamic-pituitary-adrenal (HPA) axis, th...
12 CitationsSource
#1Fernando Flexa Ribeiro Filho (UNIFESP: Federal University of São Paulo)H-Index: 8
#2Lydia Sebba Souza Mariosa (UNIFESP: Federal University of São Paulo)H-Index: 2
Last.Maria Teresa Zanella (UNIFESP: Federal University of São Paulo)H-Index: 19
view all 4 authors...
Metabolic syndrome (MS) is seen nowadays as a worldwide epidemic event associated with high cardiovascular morbi-mortality and high socioeconomic cost. The ponderal gain is an independent predictor for the development of MS, although not all obese individuals present it. On the other hand, some populations with low obesity prevalence present high prevalence of MS and cardiovascular mortality. The distribution of corporal fat is relevant and visceral fat (VF), specifically, seems to be the link b...
113 CitationsSource
ABSTRACT Visceral Fat and Metabolic Syndrome: More Than a Simple Association.Metabolic syndrome (MS) is seen nowadays as a worldwide epidemicevent associated with high cardiovascular morbi-mortality and highsocioeconomic cost. The ponderal gain is an independent predictor forthe development of MS, although not all obese individuals present it. Onthe other hand, some populations with low obesity prevalence presenthigh prevalence of MS and cardiovascular mortality. The distribution ofcorporal fat ...
INTRODUCTION: Obese people are at higher cardiovascular risk than people with normal body weight. The objective of this study was to establish the relationship between obesity, body fat distribution and cardiovascular risk factors. METHODS: Body mass index (BMI), waist-hip ratio (WHR) systolic (SBP) and diastolic blood pressure (DBP), plasma cholesterol, triglycerides and glucose levels were determined in a population of 499 overweight and obese patients (432F/67M; age 39±12.9y). RESULTS: High p...
122 CitationsSource
OBJECTIVE: To assess the effects of weight reduction with 10mg of sibutramine or placebo on blood pressure during 24 hours (ambulatory blood pressure monitoring), on left ventricular mass, and on antihypertensive therapy in 86 obese and hypertensive patients for 6 months. METHODS: The patients underwent echocardiography, ambulatory blood pressure monitoring, and measurement of the levels of hepatic enzymes prior to and after treatment with sibutramine or placebo. RESULTS: The group using sibutra...
12 Citations
#1Alessandra N. Faria (UNIFESP: Federal University of São Paulo)H-Index: 10
#2Fernando Flexa Ribeiro Filho (UNIFESP: Federal University of São Paulo)H-Index: 8
Last.Maria Teresa Zanella (UNIFESP: Federal University of São Paulo)H-Index: 19
view all 6 authors...
OBJECTIVE: To assess the effects of weight reduction with 10mg of sibutramine or placebo on blood pressure during 24 hours (ambulatory blood pressure monitoring), on left ventricular mass, and on antihypertensive therapy in 86 obese and hypertensive patients for 6 months. METHODS: The patients underwent echocardiography, ambulatory blood pressure monitoring, and measurement of the levels of hepatic enzymes prior to and after treatment with sibutramine or placebo. RESULTS: The group using sibutra...
16 CitationsSource
12